Research Institute of the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; W.F. Goodman Center for Comparative Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Mol Ther. 2014 Mar;22(3):554-566. doi: 10.1038/mt.2013.237. Epub 2013 Oct 8.
Adeno-associated virus (AAV) vectors can move along axonal pathways after brain injection, resulting in transduction of distal brain regions. This can enhance the spread of therapeutic gene transfer and improve treatment of neurogenetic disorders that require global correction. To better understand the underlying cellular mechanisms that drive AAV trafficking in neurons, we investigated the axonal transport of dye-conjugated AAV9, utilizing microfluidic primary neuron cultures that isolate cell bodies from axon termini and permit independent analysis of retrograde and anterograde axonal transport. After entry, AAV was trafficked into nonmotile early and recycling endosomes, exocytic vesicles, and a retrograde-directed late endosome/lysosome compartment. Rab7-positive late endosomes/lysosomes that contained AAV were highly motile, exhibiting faster retrograde velocities and less pausing than Rab7-positive endosomes without virus. Inhibitor experiments indicated that the retrograde transport of AAV within these endosomes is driven by cytoplasmic dynein and requires Rab7 function, whereas anterograde transport of AAV is driven by kinesin-2 and exhibits unusually rapid velocities. Furthermore, increasing AAV9 uptake by neuraminidase treatment significantly enhanced virus transport in both directions. These findings provide novel insights into AAV trafficking within neurons, which should enhance progress toward the utilization of AAV for improved distribution of transgene delivery within the brain.
腺相关病毒 (AAV) 载体在脑内注射后可沿轴突途径移动,从而转导远端脑区。这可以增强治疗性基因转移的传播,并改善需要全局校正的神经遗传疾病的治疗效果。为了更好地了解驱动 AAV 在神经元中运输的潜在细胞机制,我们研究了染料偶联的 AAV9 的轴突运输,利用微流控原代神经元培养物将细胞体与轴突末端分离,并允许对逆行和顺行轴突运输进行独立分析。进入后,AAV 被运送到非运动性的早期和再循环内体、胞吐小泡以及逆行定向的晚期内体/溶酶体隔室。含有 AAV 的 Rab7 阳性晚期内体/溶酶体具有高度的运动性,与没有病毒的 Rab7 阳性内体相比,逆行速度更快,停顿时间更短。抑制剂实验表明,这些内体中 AAV 的逆行运输由细胞质动力蛋白驱动,需要 Rab7 功能,而 AAV 的顺行运输由驱动蛋白-2 驱动,并表现出异常快速的速度。此外,通过神经氨酸酶处理增加 AAV9 的摄取量显著增强了病毒在两个方向上的运输。这些发现为 AAV 在神经元中的运输提供了新的见解,这应该有助于利用 AAV 提高脑内转基因传递的分布。